CEO Update - 29 August 2023
I return from holiday to the news that Abcam, a key British life science company founded in 1998, is to be acquired by Danaher, bringing to a conclusion a headline-grabbing intervention this year by founder Jonathan Milner. Once again, this shows the global attractiveness of a global life science company built in the UK. Jonathan already has a track record for supporting the next-generation UK life science businesses and I hope he will continue to do so with some of the new proceeds from the sale.
10 drugs to face Medicare price negotiations
The US today selected the first 10 drugs subject to Medicare price negotiations an important step in the development of the new legislation under the Inflation Reduction Act (IRA). If you need a refresher on why this matters for life science companies, take a look at the "IRA: Threats and opportunities for UK life sciences" webinar recording. This will remain a moving story, especially as there is a significant judicial challenge to the act in the US Court.
BIA Board Nomincations open
We are delighted to invite nominations from individuals interested in joining our BIA Board. Nominations for next year's board must be received by Friday, 15 September. This year, there are five places up for election for the corporate members and one for other members. If you’re interested in applying please contact company secretary, Nick Gardiner.
Steve Bates OBE
CEO, BioIndustry Association
